Recommendations Updated for Timing of Surgery After COVID-19
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
THURSDAY, June 29, 2023 -- The timing of elective surgery for patients after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is revisited in a guideline update issued by the American Society of Anesthesiologists and Anesthesia Patient Safety Foundation and published online June 19 in Anaesthesia.
Given widespread vaccination, less virulent variants, contemporary evidence, and a need to increase access to safe surgery, Kariem El-Boghdadly, M.B.B.S., from Guy's and St. Thomas' NHS Foundation Trust in London, and colleagues updated recommendations relating to the timing of elective surgeries after COVID-19 infection.
According to the recommendations, patients who develop SARS-CoV-2 symptoms within seven weeks of planned surgery should be screened, and tested if appropriate, before undergoing elective surgery. Elective surgeries should not be performed within two weeks of SARS-CoV-2 infection. A risk assessment should be conducted between two and seven weeks after SARS-CoV-2 infection, considering factors such as age, infection factors, and surgical risk. Scheduling the procedure within two and seven weeks after infection should be discussed if the patient and surgery are low risk; the risk of delay should also be considered. For patients who have fully recovered from or have had mild SARS-CoV-2 infection, there is no evidence to support delaying surgery beyond seven weeks.
"As the disease evolves and becomes less virulent and increasing numbers of the population have either been vaccinated, exposed or both, these recommendations help provide guidance on balancing the risk of delaying surgery against the risk of complications," Michael W. Champeau, M.D., president of the American Society of Anesthesiologists, said in a statement.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted June 2023
Further Support and Information on COVID-19
Read this next
ASCO: Neoadjuvant Ipilimumab + Nivolumab Ups Survival in Resectable Melanoma
WEDNESDAY, June 5, 2024 -- Neoadjuvant ipilimumab plus nivolumab followed by surgery results in longer event-free survival than surgery followed by adjuvant nivolumab among...
Odds of Death Lower With Surgery for Hip Fracture in Patients With Dementia
MONDAY, June 3, 2024 -- For community-dwelling patients with dementia and fracture of the femoral head and neck, the odds of death are lower for those treated surgically...
No Decline in Cardiovascular Events Seen With COVID-19 Vaccine After Acute Coronary Syndromes
MONDAY, June 3, 2024 -- Patients who have received at least one COVID-19 vaccine dose after acute coronary syndromes do not have a reduced risk for cardiovascular events...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.